Vectobac 12 AS

Primær information

  • Handelsnavn:
  • Vectobac 12 AS Flydende middel
  • INN (International Name):
  • H14
  • Lægemiddelform:
  • Flydende middel
  • Sammensætning:
  • 1200 ITU/mg Bacilus thuringiensis var. H14
  • Brugt til:
  • Planter
  • Medicin typen:
  • agrokemiske

Dokumenter

  • for den brede offentlighed:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for offentligheden.

Lokation

  • Fås i:
  • Vectobac 12 AS Flydende middel
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • SEGES Landbrug & Fødevarer
  • Autorisation status:
  • Udgået
  • Autorisationsnummer:
  • 22-72
  • Sidste ændring:
  • 08-02-2018

Produktresumé

LEVERANDØRBRUGSANVISNING

(Sikkerhedsdatablad)

Udarbejdet efter Arbejdsministeriets bekendtgørelse nr 485 af 16. juni 1995 om stoffer og materialer, § 16, stk. 2.

VECTOBAC

12AS

1. Produktidentifikation

VECTOBAC

12AS

Produkttype:

Biologisk insektmiddel til bekæmpelse

af larver på planter

Leverandør:

Cillus A/S

Tlf.: 4491 6055

Kobbervej 8

Fax.: 4491 6575

2730

Herlev

Kontaktperson: E. Rubæk

2. Oplysning om indholdsstoffer:

Analyse:

VECTOBAC

12AS indeholder 1200

International Toxic Units pr. mg

(1,25%) af Bacillus thuringiensis H-14.

Resten inaktive fyldstoffer (98,75%).

3. Faredeklaration

For mennesker: Undgå kontakt med huden og øjnene.

4. Førstehjælp

Øjne:

Kommer stoffet i øjnene, skylles straks

med vand og læge kontaktes.

Hud:

Forurenet tøj fjernes straks, og forure-

net hud vaskes straks med vand og

sæbe.

Indånding:

Søg frisk luft og hvile

Indtagelse:

Skyl munden, drik rigeligt vand og søg

læge.

Forbrænding:

Ikke brændbart.

5. Forholdsregler ved brand

Produktet bør så vidt muligt fjernes fra brandstedet.

Sluk med pulver, skum eller vandtåge. Hold emballa-

gerne afkølet ved oversprøjtning med vand, hvis udsat

for stærk varme. Undgå indånding af røg og gasser, der

udvikles ved branden.

6. Forholdsregler ved spild

Må ikke hældes i afløb, vandløb eller på jorden.

Evt. spild opsamles med væskeabsorberende materiale,

og dette skal sammen med tom emballage og rester af-

leveres til den kommunale modtageordning.

7. Håndtering og opbevaring

Undgå spild. Brug ansigtsskærm eller beskyttelsesbril-

ler, handsker og forklæde ved udsprøjtning.

S2 -Opbevares utilgængeligt for børn.

S13 -Må ikke opbevares sammen med fødevarer, drik-

kevarer og foderstoffer.

8. Eksponeringskontrol/Personlige værnemidler

Undgå indånding af sprøjtetågen

Undgå kontakt med huden

Brug beskyttelseshandsker. Flerlagshandsker bør fore-

trækkes. Tilsmudset tøj skiftes straks.

Vask huden efter arbejdet.

Efter sprøjtning skal planterne være tørre på bladene,

inden håndtering påbegyndes.

Følg i øvrigt Arbejdstilsynets vejledning og regler om

arbejdstøj og personlige værnemidler.

9. Fysisk-kemiske egenskaber

Tilstandsform:

Vandig suspension

Farve:

Lysebrun

Lugt:

Fermenteringsagtig

Kogepunkt:

Frysepunkt:

Flammepunkt:

ikke brændbart

Opløselighed

i vand:

Opslemning

Vægtfylde:

1,05

ca. 5

10. Stabilitet og reaktivitet

Produktet er lagerfast i mindst 2 år i uåbnet emballage.

Undgå store temperaturudsving. Undgå direkte sollys.

11. Toksikologiske oplysninger

Akut LD-50:

Ved indtagelse > 5000 mg/kg

Ved hudkontakt > 5000 mg/kg

Akut LC-50:

Ved inhalering >5,34 mg/l

Indånding:

Kan give svag irritation.

Hudkontakt:

Kan give svag irritation ved langvarig

påvirkning.

Øjnene:

Stænk i øjnene giver svag irritation

(sviden)

VECTOBAC

12AS

29.04.04

Side 2 af 2

12. Miljøoplysninger

Såvel B.t. som fyldstofferne anses for ikke særlig ska-

delig for miljøet. Se i øvrigt punkt 6.

13. Bortskaffelse

Tom emballage må ikke genanvendes til andet formål.

Tom emballage og rester afleveres til den kommunale

modtageordning.

Rengjort emballage afleveres som dagrenovation.

14. Transportoplysninger

VECTOBAC

12AS er ikke underlagt ADR, hvorfor

der ikke er specielle regler for tranport.

15. Forholdsregler ved brug:

Opbevaring:

VECTOBAC

12AS opbevares frost-

frit.

Må ikke stå i direkte sollys.

Holdbar i uåbnet emballage i mindst 2

år.

Emballagen omrystes grundigt inden det afmålte

kvantum hældes i sprøjtebeholderen under moderat

omrøring.

Tømt og skyllet emballage bortskaffes med dagre-

novationen.

Kommer væsken i øjnene, skyl da omgående med

rigeligt vand

Undgå indånding af sprøjtevæsken.

Anvend ansigtsskærm, handsker og forklæde ved

udsprøjtning.

Planterne skal være tørre inden håndtering påbe-

gyndes.

Vask sprøjteudstyret straks efter arbejdets ophør.

Der kræves ingen særlig uddannelse, dog må unge

under 18 år ikke arbejde med produktet.

16. Brugsanvisning

VECTOBAC

12AS er et biologisk bekæmpelses-

middel, der anvendes mod larver af sørgemyg

(svampemyg) i væksthuse, samt filterfluer (møg-

fluer) i rensningsanlæg og stankelbenlarver på

græsarealer.

"

VECTOBAC

12AS anvendes erhvervsmæssigt

eller privat efter behov.

"

Der er ingen behandlingsfrist. Vask hænder og ud-

styr efter endt udsprøjtning.

"

VECTOBAC

12AS sprøjtevandes på borde, i

potter og på jorden under bordene. Der vandes så

de øverste 3-4 cm af voksemediet er gennemvædet

-ca 2 ltr. væske pr m

. Gennemvanding bør have

fundet sted, inden sprøjtevanding -ikke omvendt.

"

VECTOBAC

12AS optages af sørgemyggens

larver i jorden. Efter 1-2 dages forløb standser lar-

verne fødeoptagelsen og dør.

"

Doseringen er 0,125 - 0,25% styrke i 2 ltr. vand pr.

. Svarende til, at der anvendes 2½ - 5 ml

VECTOBAC

12AS pr m

. 1 ltr. VECTOBAC

12AS rækker således til 200 - 400 m

behandlet

areal.

"

Første behandling umiddelbart efter oppotning.

Behandlingen gentages med 5 - 7 dages interval, i

alt 3 gange. Brug gule limplader til at kontrollere

om flyvningen er holdt op. VECTOBAC

12AS

kan sprøjtevandes sammen med nematoder.

"

VECTOBAC

12AS må ikke blandes med gød-

ning eller lign., der kan neutralisere virkningen -

hverken ved tankblanding eller drypvanding.

Tålsomhed:

Mange plantearter har været prøvet

uden skade, når doseringen overholdes.

Når der skiftes fra en art/sort til en an-

den, eller kulturbetingelserne ændres,

anbefales det at prøve få planter, inden

et helt parti behandles.

VECTOBAC

12AS er anerkendt af

Danmarks Jordbrugsforskning til be-

handling mod larver af sørgemyg på

prydplanter i væksthus med 5 ml pr m

2

Larver af mosestankelben på græsarealer kan være et

problem. Især hvis der året efter skal sås andre afgrø-

der. En total bekæmpelse af mosestankelben er ikke

mulig, men en væsentlig reduktion af larvebestanden

kan forventes.

Tidspunkt:

I oktober måned vælges en mild og fugtig dag. Sprøjt

sidst på dagen når larverne kommer op til overfladen

for at æde af planterne.

Dosering:

2 -2½ ltr. VECTOBAC

12AS pr. ha i mindst 400 ltr.

vand, gerne mere. Evt. i let regnvejr.

Genbehandling:

Hvis klækning af larver sker over en lang periode, kan

behandlingen gentages - evt. næste forår, fortsat med

stor fugtighed i jordoverfladen og gerne i let regn.

Læs mere om bekæmpelse af mosestankelben i ”Mar-

kens sygdomme og skadedyr”.

Udarbejdet af E. Rubæk den 29.04.2004

  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

    Anmode informationsbrochure for offentligheden.



  • Dokumenter på andre sprog er tilgængelige her

19-7-2018

July 18, 2018: Medical Device Maker AngioDynamics Agrees to Pay $12.5 Million to Resolve False Claims Act Allegations

July 18, 2018: Medical Device Maker AngioDynamics Agrees to Pay $12.5 Million to Resolve False Claims Act Allegations

July 18, 2018: Medical Device Maker AngioDynamics Agrees to Pay $12.5 Million to Resolve False Claims Act Allegations

FDA - U.S. Food and Drug Administration

18-7-2018

Orphan designation:  Gevokizumab,  for the: Treatment of chronic non-infectious uveitis

Orphan designation: Gevokizumab, for the: Treatment of chronic non-infectious uveitis

On 12 March 2013, orphan designation (EU/3/13/1111) was granted by the European Commission to Les Laboratoires Servier, France, for gevokizumab for the treatment of chronic non-infectious uveitis.

Europe - EMA - European Medicines Agency

17-7-2018

The PictSweet Company Recalls 12 Ounce Steam’ables Baby Brussel Sprouts for Undeclared Milk and Soy Allergens

The PictSweet Company Recalls 12 Ounce Steam’ables Baby Brussel Sprouts for Undeclared Milk and Soy Allergens

Bells, TN – The Pictsweet Company has recalled 960 cases of Pictsweet Farms 12-ounce Steam’ables Baby Brussels Sprouts because they may contain undeclared milk and soy allergens. People who have an allergy or severe sensitivity to milk or soy may run the risk of serious allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

13-7-2018

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product ...

FDA - U.S. Food and Drug Administration

11-7-2018

Hoofdlijnenakkoord geestelijke gezondheidszorg ondertekend

Hoofdlijnenakkoord geestelijke gezondheidszorg ondertekend

Het hoofdlijnenakkoord over de toekomst van de geestelijke gezondheidszorg is getekend door staatssecretaris Paul Blokhuis (VWS) en 12 partijen uit de geestelijke gezondheidszorg en het sociaal domein. Ze hebben afspraken gemaakt om de kwaliteit en de toegankelijkheid van de geestelijke gezondheidszorg verder te verbeteren. Het ideaalbeeld voor de toekomst van de GGZ waar partijen aan werken is dat er goed naar mensen wordt geluisterd, deze de hulp krijgen die nodig is, afgestemd op hun behoefte en dat d...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

10-7-2018

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

PrEP wordt binnen een onderzoekssetting voor een periode van vijf jaar verstrekt aan de hoogrisicogroep van mannen die seks hebben met mannen (MSM). Dat heeft minister Bruno Bruins (Medische Zorg) vandaag bekend gemaakt. Op basis van schattingen van het RIVM zullen ongeveer 6500 mannen hiervan gebruik gaan maken en kunnen hiermee  250 hiv-infecties per jaar worden voorkomen. Voor gebruikers gaat een eigen bijdrage gelden van maximaal 25%, dat komt overeen met ongeveer 12 euro per maand. Ook wordt hen gev...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

16-6-2018

Del Monte Fresh Produce N.A., Inc. Voluntarily Recalls Limited Quantity of Vegetable Trays in a Multistate Outbreak of Cyclospora Illnesses in Select Retailers in Illinois, Indiana, Iowa, Michigan, Minnesota, and Wisconsin, Because of Possible Health Risk

Del Monte Fresh Produce N.A., Inc. Voluntarily Recalls Limited Quantity of Vegetable Trays in a Multistate Outbreak of Cyclospora Illnesses in Select Retailers in Illinois, Indiana, Iowa, Michigan, Minnesota, and Wisconsin, Because of Possible Health Risk

Del Monte Fresh Produce N.A., Inc. ("Del Monte Fresh") announced today, the voluntary recall of a limited quantity of 6 oz., 12 oz. and 28 oz. vegetable trays containing fresh broccoli, cauliflower, celery sticks, carrots, and dill dip sold to select retailers in Illinois, Indiana, Iowa, Michigan, Minnesota and Wisconsin. Del Monte was notified by state agencies of the outbreak and its potential involvement.

FDA - U.S. Food and Drug Administration

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

8-6-2018

Orphan designation:  Mepolizumab,  for the: Treatment of Churg-Strauss syndrome

Orphan designation: Mepolizumab, for the: Treatment of Churg-Strauss syndrome

On 12 March 2013, orphan designation (EU/3/13/1116) was granted by the European Commission to Glaxo Group Ltd, United Kingdom, for mepolizumab for the treatment of Churg-Strauss syndrome.

Europe - EMA - European Medicines Agency

30-5-2018

12 applications for allocation of special funds related to medicinal cannabis

12 applications for allocation of special funds related to medicinal cannabis

The application deadline for the second allocation of special funds for accumulation of scientific knowledge in regard to the medicinal cannabis pilot programme has now expired. The Danish Medicines Agency received 12 applications.

Danish Medicines Agency

19-7-2018

EU/3/12/1083 (Global Regulatory Limited)

EU/3/12/1083 (Global Regulatory Limited)

EU/3/12/1083 (Active substance: Humanised single chain monoclonal antibody against CD37) - Transfer of orphan designation - Commission Decision (2018)4839 of Thu, 19 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/128/12/T/02

Europe -DG Health and Food Safety

13-7-2018

News and press releases:  Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9-12 July 2018

News and press releases: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9-12 July 2018

PRAC recommends restricting use of prostate cancer medicine Xofigo

Europe - EMA - European Medicines Agency

12-7-2018

Econor (Elanco Europe Ltd)

Econor (Elanco Europe Ltd)

Econor (Active substance: Valnemulin hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4580 of Thu, 12 Jul 2018

Europe -DG Health and Food Safety

12-7-2018

TGA presentations: The new Code - where are we at? 12 & 13 June 2018

TGA presentations: The new Code - where are we at? 12 & 13 June 2018

These presentations provided an update on the implementation of the new Therapeutic Goods Advertising Code and complaints system

Therapeutic Goods Administration - Australia

9-7-2018

Agenda:  Agenda - PRAC draft agenda of meeting 9-12 July 2018

Agenda: Agenda - PRAC draft agenda of meeting 9-12 July 2018

Europe - EMA - European Medicines Agency

27-6-2018

EU/3/12/999 (Merck Sharp and Dohme B.V.)

EU/3/12/999 (Merck Sharp and Dohme B.V.)

EU/3/12/999 (Active substance: Letermovir) - Transfer of orphan designation - Commission Decision (2018)4104 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/008/12/T/02

Europe -DG Health and Food Safety

27-6-2018

EU/3/13/1121 (Eisai GmbH)

EU/3/13/1121 (Eisai GmbH)

EU/3/13/1121 (Active substance: Lenvatinib) - Transfer of orphan designation - Commission Decision (2018)4079 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/173/12/T/01

Europe -DG Health and Food Safety

12-6-2018

Cholib (Mylan Products Limited)

Cholib (Mylan Products Limited)

Cholib (Active substance: fenofibrate / simvastatin) - Centralised - Renewal - Commission Decision (2018)3153 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2559/R/17

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3809 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/092/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3808 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/084/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/794 (Celgene Europe B.V.)

EU/3/10/794 (Celgene Europe B.V.)

EU/3/10/794 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3803 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/069/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate salt) - Transfer of orphan designation - Commission Decision (2018)3797 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/244/16/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl] acetate salt) - Transfer of orphan designation - Commission Decision (2018)3798 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/166/12/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/17/1922 (Gilead Sciences Ireland UC)

EU/3/17/1922 (Gilead Sciences Ireland UC)

EU/3/17/1922 (Active substance: Entospletinib) - Transfer of orphan designation - Commission Decision (2018)3803 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/040/17/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/888 (Gilead Sciences Ireland UC)

EU/3/11/888 (Gilead Sciences Ireland UC)

EU/3/11/888 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3802 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/152/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/887 (Gilead Sciences Ireland UC)

EU/3/11/887 (Gilead Sciences Ireland UC)

EU/3/11/887 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3801 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/020/11/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/886 (Gilead Sciences Ireland UC)

EU/3/11/886 (Gilead Sciences Ireland UC)

EU/3/11/886 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3799 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/019/11/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/17/1956 (Sangamo Therapeutics UK LTD)

EU/3/17/1956 (Sangamo Therapeutics UK LTD)

EU/3/17/1956 (Active substance: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene) - Transfer of orphan designation - Commission Decision (2018)3811 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/168/17/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/17/1955 (Sangamo Therapeutics UK LTD)

EU/3/17/1955 (Sangamo Therapeutics UK LTD)

EU/3/17/1955 (Active substance: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene) - Transfer of orphan designation - Commission Decision (2018)3810 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/167/17/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/16/1615 (Gilead Sciences Ireland UC)

EU/3/16/1615 (Gilead Sciences Ireland UC)

EU/3/16/1615 (Active substance: 2-ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate) - Transfer of orphan designation - Commission Decision (2018)3804 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/197/15/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/16/1802 (Quality Regulatory Clinical Ireland Limited)

EU/3/16/1802 (Quality Regulatory Clinical Ireland Limited)

EU/3/16/1802 (Active substance: Ivosidenib) - Transfer of orphan designation - Commission Decision (2018)3805 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/197/16/T/01

Europe -DG Health and Food Safety

11-6-2018

 Minutes of the PRAC meeting 9-12 Apil 2018

Minutes of the PRAC meeting 9-12 Apil 2018

Europe - EMA - European Medicines Agency

11-6-2018

 Minutes of the PRAC meeting 9-12 April 2018

Minutes of the PRAC meeting 9-12 April 2018

Europe - EMA - European Medicines Agency

4-6-2018

Venclyxto (AbbVie Deutschland GmbH and Co. KG)

Venclyxto (AbbVie Deutschland GmbH and Co. KG)

Venclyxto (Active substance: venetoclax) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3633 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4106/T/12

Europe -DG Health and Food Safety

2-6-2018

EU/3/12/1046 (Novartis Europharm Limited)

EU/3/12/1046 (Novartis Europharm Limited)

EU/3/12/1046 (Active substance: Mavoglurant) - Transfer of orphan designation - Commission Decision (2018)3631 of Sat, 02 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/059/12/T/01

Europe -DG Health and Food Safety

30-5-2018

Atosiban SUN (Sun Pharmaceutical Industries Europe BV)

Atosiban SUN (Sun Pharmaceutical Industries Europe BV)

Atosiban SUN (Active substance: atosiban) - Centralised - Renewal - Commission Decision (2018)3469 of Wed, 30 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2329/R/12

Europe -DG Health and Food Safety

21-5-2018

EU/3/07/522 (Best Regulatory Consulting Ltd)

EU/3/07/522 (Best Regulatory Consulting Ltd)

EU/3/07/522 (Active substance: (manganese, dichloro [(4aR, 13aR, 17aR, 21aR)-1, 2, 3, 4, 4a, 5, 6, 12, 13, 13a, 14, 15, 16, 17, 17a, 18, 19, 20, 21, 21a-eicosahydro-11, 7-nitrilo-7H-dibenzo[ b,h] [1,4,7,10] tetraazacycloheptadecine-?N5, ?N13, ?N18, ?N21, ?N22]-)) - Transfer of orphan designation - Commission Decision (2018)3136 of Mon, 21 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/089/07/T/01

Europe -DG Health and Food Safety

16-5-2018

EU/3/13/1116 (GlaxoSmithKline Trading Services Limited)

EU/3/13/1116 (GlaxoSmithKline Trading Services Limited)

EU/3/13/1116 (Active substance: Mepolizumab) - Transfer of orphan designation - Commission Decision (2018)3046 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/174/12/T/01

Europe -DG Health and Food Safety

16-5-2018

EU/3/12/1063 (Novartis Europharm Limited)

EU/3/12/1063 (Novartis Europharm Limited)

EU/3/12/1063 (Active substance: Panobinostat) - Transfer of orphan designation - Commission Decision (2018)3041 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/113/12/T/01

Europe -DG Health and Food Safety

16-5-2018

EU/3/12/1034 (Novartis Europharm Limited)

EU/3/12/1034 (Novartis Europharm Limited)

EU/3/12/1034 (Active substance: Humanised monoclonal antibody against P-selectin) - Transfer of orphan designation - Commission Decision (2018)3040 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/026/12/T/02

Europe -DG Health and Food Safety